Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB) led the round. Continuing investments were made by Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.

With the mission to tackle the massive oncology dilemma, Elephas is developing an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. Their unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor response to immunotherapies using the latest advances in metabolic imaging.